BrainsWay Ltd. (BWAY)
BrainsWay Ltd. (BWAY) Stock Price, Analysis & Data
| Bid | 10.99 |
| Market Cap | 660.96M |
| Revenue (ttm) | 56.22M |
| Net Income (ttm) | 8.76M |
| Beta | 0.10 |
| EPS (ttm) | 0.22 |
| PE Ratio (ttm) | 74.86 |
| Forward PE | 33.84 |
| P/B (ttm) | 8.82 |
| P/S (ttm) | 11.76 |
| Earnings Date | Nov 15, 2023 |
| Ask | 19.71 |
| Volume | 230,113 |
| Avg. Volume (20D) | 129,470 |
| Open | 16.95 |
| Previous Close | 16.60 |
| Day's Range | 16.32 - 17.29 |
| 52-Week Range | 6.26 - 17.40 |
| Analyst | Strong Buy |
| Price Target | 18.8 (14.15%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic...
Financial Performance
In 2025, BrainsWay's revenue was 52.23M, an increase of 27.33% compared to the previous year's 41.02M. Earnings were 7.63M, an increase of 161.31%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for BWAY stock is "Strong Buy". The 12-month stock price forecast is 18.8, which is upside of 14.15% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
